Olmutinib Suppliers list
Company Name: Nanjing Gold Pharmaceutical Technology Co. Ltd.
Tel: 025-84209270 15906146951
Email: wgp@nanjing-pharmaceutical.com
Products Intro: Product Name:HM71224
Purity:99% Package:1000KG;;100KG;10KG;5KG;1KG
Tel: +86 21 5161 9050/ 5187 7795
Email: ivan@atkchemical.com
Products Intro: CAS:1353562-97-2
Purity:98% HPLC Package:5MG;10MG;50MG;100MG,1G,5G
Company Name: BOC Sciences
Tel: 1-631-485-4226
Email: inquiry@bocsci.com
Products Intro: Product Name:Olmutinib
Company Name: career henan chemical co
Tel: 0086-371-86658258
Email: factory@coreychem.com
Products Intro: Product Name:Olmutinib
Purity:99% Package:1g;1USD
Company Name: Target Molecule Corp
Tel: 781-999-5354
Email: marketing@targetmol.com
Products Intro: Product Name:Olmutinib;HM61713, BI 1482694;BI 1482694;HM61713;HM61713
Purity:97.46% Package:5 mg;10 mg;25 mg;50 mg;100 mg;200 mg;1 mL * 10 mM (in DMSO);2 mg Remarks:REAGENT;FOR LABORATORY USE ONLY

Lastest Price from Olmutinib manufacturers

  • Olmutinib
  • US $1.00 / g
  • 2020-02-02
  • CAS:1353550-13-6
  • Min. Order: 1g
  • Purity: 99%
  • Supply Ability: 200g
Olmutinib Basic information
Product Name:Olmutinib
Synonyms:HM71224;HM-71224;Olmutinib;Olmutinib, HM71224;N-(3-(2-(4-(4-methylpiperazin-1-yl)phenylamino)thieno[3,2-d]pyrimidin-4-yloxy)phenyl)acrylamide dihydrochloride monohydrate;N-(3-(2-(4-(4-methylpiperazin-1-yl)phenylamino)thieno[3,2-d]pyrimidin-4-yloxy)phenyl)acrylamide;N-[3-[[2-[[4-(4-Methyl-1-piperazinyl)phenyl]amino]thieno[3,2-d]pyrimidin-4-yl]oxy]phenyl]-2-propenamide;HM71224, Olmutinib
Product Categories:
Mol File:1353550-13-6.mol
Olmutinib Structure
Olmutinib Chemical Properties
density 1.336±0.06 g/cm3(Predicted)
Safety Information
MSDS Information
Olmutinib Usage And Synthesis
DescriptionOlmutinib, codeveloped by Boehringer Ingelheim and Hanmi Pharmaceutical Co., was approved by the Korean Ministry of Food and Drug Safety (MFDS) for treatment of locally advanced or metastatic EGFR T790 M mutation-positive non-small cell lung cancer (NSCLC). Olmutinib serves as a third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI), which is being used as an oral therapy for patients who have previously been treated with an alternate EGFR TKI. Firstand second-generation EGFR TKIs, which bind reversibly and irreversibly to the TK domain, respectively, are both generally effective at onset of treatment but result in development of resistance within the first year of treatment. Thirdgeneration EGFR TKIs such as olmutinib have demonstrated the ability to covalently bind to the kinase domain of EGFR while sparing wild-type EGFR, leading to irreversible inhibition of both EGFR mutations and the T790 M mutation, which is linked to EGFR TKI resistance.
Chemical SynthesisSynthetically, olmutinib can be accessed in two steps beginning with 2,4-dichloro-thieno[3,2-d]pyrimidine (147), which is commercially available and can be prepared in two steps from urea and 3-aminothiophene 2- carboxylate. Nucleophilic addition of N-(3-hydroxyphenyl)-2- propenamide (148) to 147 proceeded with complete regioselectivity via treatment with K2CO3 in warm DMSO, smoothly providing the desired diaryl ether 149 in 87% yield after crystallization from isopropanol and water. From 149, substitution with commercially available piperazinyl aniline 150 under acidic heating conditions (DMA, IPA, TFA, 90 °C) provided olmutinib in 82% yield. After recrystallization, olmutinib (XVI) was obtained in 60% overall yield and 99.1% purity.

Tag:Olmutinib(1353550-13-6) Related Product Information
AVE8062A Ombrabulin Genistein Mubritinib Enzalutamide Rivaroxaban Zoledronic acid Dacomitinib (PF299804) Irbinitinib XL-647 AZD 3759 AG 1478 HYDROCHLORIDE OSI-420 Anlotinib EGF816 Neratinib Poziotinib (HM781-36B) CO-1686